Workflow
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Core Insights - Quantum BioPharma Ltd. has appointed Dr. Jack Antel as a new clinical advisor for its multiple sclerosis program, Lucid-MS, which is designed to inhibit demyelination in MS [1][4][5] - Dr. Antel is a prominent clinical neurologist and expert in MS, with extensive experience and numerous publications in the field [2] - The company aims to advance Lucid-MS into a Phase 2 clinical trial to assess its efficacy in MS patients [4] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse [8][9] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [9] - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is associated with royalty payments from sales of the unbuzzd™ product [9]